A drug candidate dubbed Aes-103 that was developed by researchers at the US National Institute of Health's National Center for Advancing Translational Sciences has been acquired by Baxter International's BioScience business.

According to NIH, Aes-103 was developed to target the underlying molecular mechanism of sickle cell disease, and Baxter will now usher the drug through the next stages of clinical development with an eye toward obtaining regulatory approval and commercializing the drug.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.